Table 1. Baseline demographic and clinical characteristics of the study patients.
| Variable | Total (n = 149) |
|---|---|
| Age (years) | 58.59 ± 12.93 |
| Gender (male %) | 53.7 |
| BMI (kg/m2) | 22.69 ± 3.40 |
| Cardiovascular | |
| Diabetes (%) | 45 |
| Previous CVD (%) | 33.6 |
| Smoking habit (%) | 40.9 |
| Blood pressure (mmHg) | |
| Systolic | 143.45 ± 27.26 |
| Diastolic | 73.66 ± 14.43 |
| MAP | 96.93 ± 16.99 |
| Antihypertensive drugs (%) | |
| RAS blockers | 55.7 |
| Beta-blockers | 51 |
| CCB | 48.3 |
| Anti-platelet agents (%) | 96 |
| Statins (%) | 30.9 |
| Ca-based P binder (%) | 80.5 |
| Vitamin D analogue (%) | 26.8 |
| HD | |
| Dialysis duration (months) * | 53 (19–71) |
| Dialysate Ca concentration (mmol/L) | 1.60 ± 0.21 |
| VCS | |
| VCS-baseline | 5.03 ± 5.89 |
| VCS-last follow up | 6.63 ± 6.81 |
| ΔVCS † | 1.60 ± 2.91 |
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; MAP, mean artery pressure; RAS, renin-angiotensin system; CCB, calcium channel blocker; Ca, calcium; VCS, vascular calcification score
* Median, interquartile range
† ΔVCS (difference between last follow-up year VCS and baseline VCS)